Abstract. A dengue-2 (DEN-2) DNA vaccine coding for the premembrane and envelope (E) proteins and a recombinant fusion protein containing the B domain of the DEN-2 E protein fused to the maltose-binding protein (MBP) of Escherichia coli both elicited neutralizing antibody in mice. In order to achieve more rapid protective immunity as well as to increase the persistence of neutralizing antibody, we primed mice with the DNA vaccine (D), the recombinant MBP protein (R), or both (RD) given simultaneously, and then boosted twice with either the R ( (40), and the D/R/R group had a slightly higher titer (156) than these 2 groups. The predominant antibody subclass for the D/D/D mice was immunoglobulin (Ig) G2a, similar to mice infected with live virus. The R/R/R mice showed an exclusive IgG1 antibody response, and the RD/RD/RD response also was predominantly IgG1. The antibody subclass pattern of the R/D/D and D/R/R mice showed a more balanced distribution of both IgG1 and IgG2a. Investigating the neutralizing capacity of antibody subclasses suggested that both IgG1 and IgG2a could neutralize DEN-2 virus. Our observations indicate that the combination RD prime-boost regimen warrants further investigation as a vaccine strategy to prevent dengue infection.
INTRODUCTION
Dengue (DEN) viruses are members of the family Flaviviridae and exist as 4 antigenically distinct serotypes. These mosquito-borne viruses are estimated to cause up to 100 million infections annually. Most clinical infections result in a self-limited, acute, febrile disease called dengue fever, but several hundred thousand cases of the more severe, lifethreatening, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) also occur annually. [1] [2] [3] Although successful vaccines against other flaviviruses such as yellow fever and Japanese encephalitis have been developed, there is currently no approved vaccine available for dengue. 4 Even though promising preliminary results were reported by Vaughn and others, 5 attempts to produce cell culture derived live attenuated or recombinant protein subunit dengue vaccines have had limited success to date. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] A potential problem associated with the development of an effective vaccine to protect against dengue virus infections is the occurrence of DHF and DSS predominantly in people who have had a previous dengue infection or in infants born to dengue-immune mothers. 2, 20 A person who has experienced a single dengue virus infection remains susceptible to the other 3 serotypes of dengue virus. It is thought that cross-reactive, nonneutralizing antibody from the first dengue infection combines with the virus (different dengue serotype), causing the second infection to form antigen-antibody complexes. 3 These antigen-antibody complexes apparently attach to Fc receptors on the surface of mononuclear phagocytes, increasing the efficiency of infection of these target cells compared with free-circulating dengue virus. A similar phenomenon apparently occurs in infants born to dengue-immune mothers once the level of passively acquired antibody wanes below the neutralizing end-point. 20 This antibody-dependent enhancement of infection is thought to be an important contributing factor to DHF-DSS. Because nonneutralizing antibodies induced by a vaccine could theoretically increase the risk for severe disease, an effective dengue vaccine should induce high-titered and long-lasting neutralizing antibodies against each of the 4 serotypes. Natural dengue infections lead to the development of long-term homologous protective immunity. Some infected people maintain detectable levels of neutralizing antibody to the homologous serotype for at least 40 years, and the presence of neutralizing antibody is thought to correlate with protection. 13, 21, 22 Our previous studies have demonstrated that a recombinant fusion protein containing 103 amino acids of the B domain of the DEN-2 envelope (E) protein fused to the maltose-binding protein (MBP) of Escherichia coli, and a DEN-2 DNA vaccine containing the premembrane (prM) and E genes were both immunogenic in mice and induced anti-DEN neutralizing antibody. 25, 26 However, levels of neutralizing antibodies waned over time with both vaccine preparations. Several reports have shown that the use of a combination of a DNA vaccine and a recombinant protein in a prime-boost strategy can induce higher antibody titers than either vaccine alone. [27] [28] [29] In this study, we tested different prime-boost strategies with the DEN-2 DNA vaccine and the recombinant DEN-2 MBP fusion protein to determine if the level of DEN-2 neutralizing antibody induced could be increased and prolonged compared with either vaccine used alone.
MATERIALS AND METHODS

Virus.
Cell culture supernatant harvested from Vero cells infected with DEN-2 (New Guinea C) was used as virus stock for the plaque reduction neutralization test (PRNT) and to prepare antigen for the enzyme-linked immunosorbent assay (ELISA).
Plaque-reduction neutralization assay. Plaque-reduction neutralization tests were performed as previously described. 30 Monkey kidney (LLC-MK2) cell monolayers were seeded in 6-well plates (Falcon; Becton Dickinson, Lincoln Park, NJ) and incubated at 37ЊC in a CO 2 incubator. Sera from immunized mice were tested by means of 2-fold dilutions starting at 1:20. Plaques were visualized on Day 7 by staining with 0.02% neutral red in Hanks balanced salt solution. Each mouse serum was tested in duplicate, and the number of plaques reported was the average of the 2 determinations. The percentage of the reduction of plaques was calculated by comparison of the results obtained with sera from unimmunized mice, and the dilution at which 50% plaque reduction occurred (PRNT 50 titer) was determined by probit analysis.
Preparation of plasmid DNA. The DEN-2 plasmid construct (p1012D2ME) was prepared as previously described. 25 Briefly, the DEN-2 (New Guinea C) prM and E gene sequences (bases 290-2345) were cloned into the expression vector pVR1012 (Vical, San Diego, CA). The pVR1012 vector contains a human cytomegalovirus early promoter and intron sequences, a multiple cloning site, and the bovine growth hormone gene termination signals. It has a kanamycin resistance gene and an E. coli origin of replication. There are no eukaryotic replication origins and the plasmid has been used in various animal studies including primates. Plasmids were transformed into E. coli DH5 cells and purified by alkaline lysis and chromatography (Sephacryl S-1000) by use of standard techniques. 31 Preparation of recombinant fusion protein.
The preparation of the DEN-2 MBP fusion protein was previously described. 26 Briefly, a gene fragment encoding amino acids 298-400 (B domain) of the DEN-2 (New Guinea C) virus envelope protein was expressed as a fusion protein with the MBP of E. coli. The fusion protein was purified by amylose affinity chromatography and polyacrylamide gel electrophoresis.
Enzyme-linked immunosorbent assay. Antigen was prepared by centrifugation (27,000 rpm at 20ЊC) of clarified DEN-2 infected and uninfected Vero cell supernatant for 2 hr. Pellets were resuspended in phosphate-buffered saline (PBS) and pelleted again in 10% glycerol in 1 M Tris, pH 8.0; 5 M NaCl; 0.5 M EDTA (TNE) at 27,000 rpm for 2 hr at 20ЊC. Purified virions and control antigen were resuspended in PBS and stored at Ϫ20ЊC until used. The analysis of sera from immunized mice for DEN-2 antibodies was carried out as previously described. 26 Briefly, microtiter plate wells were coated with purified DEN-2 virions in PBS at 4ЊC overnight, followed by blocking with 5% nonfat dry milk in PBS-0.01% Tween 20 for 1 hr at 37ЊC. Plates were then incubated with the test sera diluted 1:100 in blocking buffer for 1 hr at 37ЊC. The secondary antibody was peroxidase-conjugated goat anti-mouse immunoglobulin (Ig) AϩGϩM (Kirkegaard and Perry, Gaithersburg, MD) diluted in blocking solution and incubated for 1 hr at 37ЊC. For the antibody subclass ELISA, peroxidase-conjugated goat antimouse IgG1, IgG2a, IgG2b, or IgG3 (Southern Biotechnology Associates, Birmingham, AL) was used. The 2.2Ј-azinodi[3-ethyl-benzthiazoline sulfonate (6)] peroxidase substrate system (Kirkegaard and Perry) was used to visualize DEN-2-specific antibody. The assays were performed in duplicate and the net optical density (OD) values were determined by subtracting the absorbance of test serum with negative control antigen from the absorbance of test serum with the dengue antigen. The cutoff value for seropositivity was set at Ն 0.10 because the mean adjusted OD ϩ 3 standard deviations for negative control sera was consistently below this value. For the subclass analysis, 2-fold serial dilutions of the test sera (pooled from each group of mice) starting at 1:100 were added to the antigen wells, and the groups were compared at the serum dilution at which the OD was 1.0. 32 Mouse immunizations. Groups of 6-week-old female BALB/c mice (Jackson Laboratories, Bar Harbor, ME) were inoculated with 50 g of the DEN-2 DNA vaccine (D) in PBS intradermally into the base of the tail and 100 g of the DEN-2 B domain MBP fusion protein (R) adsorbed on 0.1% aluminum hydroxide (alum) intramuscularly into the hind quadriceps. Statistical analysis. Logarithmic transformations of the reciprocal PRNT 50 titers of the mice in each immunization group were made, and the mean log titers were compared by analysis of variance. The mean log titers were converted to geometric mean (GM) titers for presentation. P values were calculated by the computer software Epi Info, version 6.02 (USD, Stone Mountain, GA). A P value of 0.005 was considered significant because there were 10 possible comparisons with 5 study arms.
The animal-based research in this study was reviewed and approved by the Naval Medical Research Center's Animal respectively. When the experiment was terminated on Day 389 after priming, the high PRNT titers for the RD/RD/RD group were sustained (Յ 2-fold decrease) in 80% of the remaining 5 mice; titers of the R/R/R group had dropped (Ն 2-fold decrease) in 60% of the remaining mice (data not shown).
Dengue-specific IgG subclass antibody responses. Dengue-specific subclass responses for the D/D/D group on Day 61 were predominantly IgG2a in similar ratios to mice that were infected with live DEN-2 virus (Table 2) , although the overall antibody levels were lower with D/D/D than live virus. The R/R/R group, on the other hand, developed predominantly IgG1 antibody because no IgG2a antibody was detected, and the RD/RD/RD group also showed predominantly IgG1. The antibody subclass patterns of the R/D/D and D/R/R groups were similar with IgG1 and IgG2a represented equally, although the titers of both subclasses were much higher in the latter group. No substantial changes in antibody subclass level or distribution were observed when measured again on Day 260 (data not shown).
Neutralizing ability of individual antibody subclasses. Antibody subclass levels of Day 61 sera from some individual mice from the DEN-2 recombinant and DEN-2 DNA vaccine control groups were measured to determine whether neutralizing antibody was predominantly associated with a particular IgG subclass ( Table 3 ). The results suggest that neutralizing activity can be associated with either IgG1 or IgG2a antibody. DISCUSSION Our results indicate that priming and boosting with the combination of the dengue DNA vaccine and the dengue recombinant subunit vaccine can rapidly generate high titers of long-lasting neutralizing antibodies in mice. It was shown that neutralizing antibody titers elicited by the DNA vaccine were boostable by the addition of the recombinant subunit vaccine (Table 1) and that 3 immunizations were required to reach the high titers observed. Recent reports indicated that DNA priming against malarial blood-stage antigen followed by a protein boost resulted in a high titered and long-lasting anamnestic response in mice. 27 Simian immunodeficiency vi- rus (SIV)-gp120 DNA priming followed by a vaccinia recombinant increased protective immunity in rhesus macaques, and human immunodeficiency virus (HIV)-gp120 DNA followed by a recombinant gp120 protein subunit resulted in elevated titers of neutralizing antibodies against human immunodeficiency virus type 1 in mice and guinea pigs. 28, 29 In our study, where mice were primed with DNA and boosted twice with the recombinant protein, significantly higher titers of neutralizing antibodies were observed as Sera from mice immunized with the DNA vaccine alone were more reactive in the ELISA than sera from mice immunized with the recombinant vaccine only. These differences in ELISA reactivity may reflect the larger number of total epitopes available in the DNA vaccine that encodes the entire membrane and envelope genes, as compared with the 103 amino acids available from the recombinant vaccine. However, higher neutralizing antibody titers were detected in response to the recombinant vaccine, whereas the DNA vaccine alone resulted in modest levels of neutralizing antibodies. This lack of correlation between total antibody levels measured by ELISA and neutralizing antibody titers in 
Ͻ100 Ͻ100 Ͻ100 Ͻ100 Ͻ100 260 * DEN-2 ϭ dengue-2; Ig ϭ immunoglobulin. The dilution of pooled serum for each group at which the enzyme-linked immunosorbent assay optical density was 1.0.
† Sera were collected 4 weeks after intracerebral inoculation with DEN-2 virus. our study is not surprising because neutralizing antibodies probably represent a subset of total antibody, and levels of neutralizing antibody may be related to the availability of neutralizing epitopes.
The high neutralizing antibody titers in response to the recombinant vaccine may be due to the large amount of DEN-2-specific neutralizing epitopes supplied at each immunization, in contrast to the number of specific neutralizing epitopes secreted in vivo in response to plasmid DNA. We have previously shown that the recombinant vaccine contains epitopes reactive with DEN-2 type-specific neutralizing monoclonal antibodies 3H5 and 6B6 and several other DEN-2-specific, neutralizing, monoclonal antibodies have also been mapped to the B domain of the DEN-2 virus envelope protein. [22] [23] [24] 26 It is conceivable that the amount of protein produced by the plasmid DNA in the cell may be too low for optimal CD4 ϩ T cell stimulation and subsequent B-cell proliferation and differentiation. The advantage of DNA vaccines is thought to reside in their ability to express foreign antigen inside the cell and access the endogenous pathway, leading to presentation by class I major histocompatibility antigens (MHC I). Antigen presentation on the cell surface in the context of MHC class I molecules is believed to activate cytotoxic T lymphocytes and induce cell-mediated immune responses. Cytotoxic T lymphocytes responses are considered to be important for controlling and sometimes clearing a viral infection. However, neutralizing antibodies are thought to be the primary line of defense from reinfection in nature. 33 We have previously shown that a DEN-1 prM and E DNA vaccine secreted envelope protein in transfected cells and appeared to form viruslike particles that induced long-lasting neutralizing antibodies in mice. 34 In contrast, protein vaccines get processed and presented to T lymphocytes by professional antigen presenting cells, primarily in association with MHC class II molecules leading to CD4 ϩ T-cell activation associated with humoral immune responses. Resulting neutralizing antibodies are thought to be critical to protection from infection with dengue virus. Kliks and others 20 demonstrated that infants of dengue-immune mothers were protected from dengue fever for several months after birth. This protection is related to the level of maternal antibodies, and as these antibodies decay, infants become susceptible to dengue fever and DHF. Because cell-mediated immunity is not transferred placentally, protection during infancy implies that humoral immunity is sufficient to protect from an infectious pathogen. 35 In addition, antibody transfer studies in animals also indicated that antibodies can be sufficient for the protection against dengue virus infection. 22 An effective dengue vaccine however, may have to induce CD8 ϩ and CD4 ϩ T-cell responses and neutralizing antibody to provide a more broad based and potentially durable immune response.
The effect of our vaccine components can be seen in the subclass of antibodies produced in mice. The protein (R/R/ R) vaccine elicited exclusively IgG1 antibody, which is usually associated with the Th2 subset of CD4 ϩ T cells. The Th2 subset produces cytokines such as interleukin-4 and interleukin-5 that help B cells to differentiate and is associated with humoral immune responses. 36 The DNA (D/D/D) vaccine, on the other hand, produced a much broader antibody subclass response, with predominantly IgG2a antibodies followed by IgG2b and IgG1 in ratios similar to the response induced by live dengue virus, although the magnitude of the response to the vaccine was lower. IgG2a antibody in mice is usually associated with the Th1 subset of CD4 ϩ T cells secreting interferon gamma and tumor necrosis factor leading to the induction of cell-mediated immune responses. 36 The D/R/R and R/D/D strategies generated evenly distributed subclass responses, suggesting a more balanced induction of cell-mediated and humoral immune response. Interestingly, the RD/RD/RD strategy resulted in predominantly IgG1 antibody, but also some IgG2a and IgG2b antibody that may be attributed to the DNA component of the vaccine.
In an effort to assess the relationship of IgG subclasses and their ability to neutralize virus in vitro, we tested individual mice from the DNA and recombinant control groups. Others have reported a correlation of IgG2a responses with neutralizing antibody titers. 37, 38 However, our results suggest that neutralizing activity can also be associated with IgG1 antibodies because mice immunized with recombinant protein alone have no detectable IgG2a antibody at a 1:100 dilution (OD Ͻ 0.10) in association with high titers of neutralizing antibodies (Tables 1 and 3) .
The magnitude and sustained antibody response of the combined recombinant protein and DNA arm described in this study may be the result of the stimulation of T cells through both MHC I and MHC II proteins. We hypothesize that inoculation with plasmid DNA allows for more efficient presentation of the foreign antigen by MHC class I molecules; uptake of soluble protein in response to both the plasmid DNA as well as the recombinant fusion protein allows for presentation by MHC class II molecules for optimal T helper and ultimately B-cell stimulation. The DNA vaccine may provide an antigenic reservoir that is continuously stimulating the immune system, thereby adding to the longevity of the immune response and secretion of viruslike particles adding to the humoral response. This DNA and protein vaccine combination strategy resulted in rapid high-titered and long-lasting neutralizing antibodies, accessing both arms of the adaptive immune system, and therefore has the potential to overcome possible deficiencies that may arise when vaccination against dengue infection that use DNA or protein subunit vaccines alone are used. Further studies are required to demonstrate actual cytokines secreted in response to DNA and protein combination vaccines and to compare the duration of the immune responses.
